Bionomics Limited Release: BNC105 Phase I/II Trial Achieves A High Response Rate In Ovarian Cancer

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ADELAIDE, South Australia, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO) (ADR:BMICY) has received positive results in the Phase I clinical trial of its cancer drug candidate BNC105 in women with ovarian cancer.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC